229 related articles for article (PubMed ID: 7510833)
21. Identification of aprt gene mutations induced in repair-deficient and P450-expressing CHO cells by the food-related mutagen/carcinogen, PhIP.
Wu RW; Wu EM; Thompson LH; Felton JS
Carcinogenesis; 1995 May; 16(5):1207-13. PubMed ID: 7767987
[TBL] [Abstract][Full Text] [Related]
22. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.
Anderson RD; Berger NA
Mutat Res; 1994 Aug; 309(1):109-42. PubMed ID: 7519727
[TBL] [Abstract][Full Text] [Related]
23. Targeted base substitutions and small deletions induced by neocarzinostatin at the APRT locus in plateau-phase CHO cells.
Wang P; Povirk LF
Mutat Res; 1997 Jan; 373(1):17-29. PubMed ID: 9015149
[TBL] [Abstract][Full Text] [Related]
24. Effects of base mutations on topoisomerase II DNA cleavage stimulated by mAMSA in short DNA oligomers.
Capranico G; Tinelli S; Zunino F; Kohn KW; Pommier Y
Biochemistry; 1993 Jan; 32(1):145-52. PubMed ID: 8380330
[TBL] [Abstract][Full Text] [Related]
25. Illegitimate recombination induced by DNA double-strand breaks in a mammalian chromosome.
Phillips JW; Morgan WF
Mol Cell Biol; 1994 Sep; 14(9):5794-803. PubMed ID: 8065314
[TBL] [Abstract][Full Text] [Related]
26. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
27. Analysis of topoisomerase I and II cleavage sites on the Drosophila actin and Hsp70 heat shock genes.
Kroeger PE; Rowe TC
Biochemistry; 1992 Mar; 31(9):2492-501. PubMed ID: 1312349
[TBL] [Abstract][Full Text] [Related]
28. An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.
Hong G; Kreuzer KN
Mol Cell Biol; 2000 Jan; 20(2):594-603. PubMed ID: 10611238
[TBL] [Abstract][Full Text] [Related]
29. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives.
Huff AC; Robinson RG; Evans AC; Selander KN; Wentland MP; Rake JB; Coughlin SA
Anticancer Drug Des; 1995 Apr; 10(3):251-76. PubMed ID: 7748459
[TBL] [Abstract][Full Text] [Related]
30. Mutagenicity of topoisomerase-active agents in bacteriophage T4.
DeMarini DM; Lawrence BK
Teratog Carcinog Mutagen; 1988; 8(5):293-301. PubMed ID: 2905838
[TBL] [Abstract][Full Text] [Related]
31. Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes.
Woodworth DL; Kreuzer KN
Genetics; 1996 Jul; 143(3):1081-90. PubMed ID: 8807283
[TBL] [Abstract][Full Text] [Related]
32. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase II cleavage in chromatin.
Udvardy A; Schedl P; Sander M; Hsieh TS
J Mol Biol; 1986 Sep; 191(2):231-46. PubMed ID: 3027349
[TBL] [Abstract][Full Text] [Related]
34. Stimulation of site-specific topoisomerase II-mediated DNA cleavage by an N-methylpyrrolecarboxamide-anilinoacridine conjugate: relation to DNA binding.
Fossé P; René B; Saucier JM; Hénichart JP; Waring MJ; Colson P; Houssier C; Bailly C
Biochemistry; 1994 Aug; 33(33):9865-74. PubMed ID: 8060993
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Pommier Y; Orr A; Kohn KW; Riou JF
Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
[TBL] [Abstract][Full Text] [Related]
36. Mutagenicity and clastogenicity of teniposide (VM-26) in L5178Y/TK +/- -3.7.2C mouse lymphoma cells.
DeMarini DM; Brock KH; Doerr CL; Moore MM
Mutat Res; 1987 Mar; 187(3):141-9. PubMed ID: 3821767
[TBL] [Abstract][Full Text] [Related]
37. Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons.
Deweese JE; Osheroff N
Biochemistry; 2009 Feb; 48(7):1439-41. PubMed ID: 19166355
[TBL] [Abstract][Full Text] [Related]
38. Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs.
Pommier Y; Capranico G; Orr A; Kohn KW
J Mol Biol; 1991 Dec; 222(4):909-24. PubMed ID: 1662289
[TBL] [Abstract][Full Text] [Related]
39. An in vitro approach to identifying specificity determinants of mutagenesis mediated by DNA misalignments.
Papanicolaou C; Ripley LS
J Mol Biol; 1991 Oct; 221(3):805-21. PubMed ID: 1942031
[TBL] [Abstract][Full Text] [Related]
40. Site-specific frame-shift mutagenesis by the 1-nitropyrene-DNA adduct N-(deoxyguanosin-8-y1)-1-aminopyrene located in the (CG)3 sequence: effects of SOS, proofreading, and mismatch repair.
Malia SA; Vyas RR; Basu AK
Biochemistry; 1996 Apr; 35(14):4568-77. PubMed ID: 8605207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
